Trial · NCT03643965
Results by group62
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 62
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part A: Ratio of Urine Protein to Creatinine Ratio (UPCR) at 9 Months Compared to Baseline | Nefecon | 0.69 | 96% Confidence Interval 0.61 to 0.79 | ratio | |
| Part A: Ratio of Urine Protein to Creatinine Ratio (UPCR) at 9 Months Compared to Baseline | Placebo Oral Capsule | 0.95 | 96% Confidence Interval 0.83 to 1.08 | ratio | |
| Part B: Time-weighted Average of Estimated Glomerular Filtration Rate (eGFR) | Nefecon | 0.96 | 95% Confidence Interval 0.93 to 0.98 | mL/min/1.73m2 | |
| Part B: Time-weighted Average of Estimated Glomerular Filtration Rate (eGFR) | Placebo Oral Capsule | 0.87 | 95% Confidence Interval 0.84 to 0.89 | mL/min/1.73m2 | |
| Part A: Ratio of eGFR at 9 Months | Nefecon | 1.00 | 95% Confidence Interval 0.96 to 1.03 | mL/min/1.73m2 | |
| Part A: Ratio of eGFR at 9 Months | Placebo Oral Capsule | 0.93 | 95% Confidence Interval 0.90 to 0.96 | mL/min/1.73m2 | |
| Part A: Ratio of eGFR at 12 Months | Nefecon | 0.97 | 95% Confidence Interval 0.93 to 1.01 | mL/min/1.73m2 | |
| Part A: Ratio of eGFR at 12 Months | Placebo Oral Capsule | 0.91 | 95% Confidence Interval 0.88 to 0.95 | mL/min/1.73m2 | |
| Part A: Ratio of Urine Albumin to Creatinine Ratio (UACR) at 9 Months | Nefecon | 0.64 | 95% Confidence Interval 0.55 to 0.75 | g/gram | |
| Part A: Ratio of Urine Albumin to Creatinine Ratio (UACR) at 9 Months | Placebo Oral Capsule | 0.93 | 95% Confidence Interval 0.80 to 1.09 | g/gram | |
| Part B: Time to 30% Reduction in eGFR | Nefecon | 21 | Participants | ||
| Part B: Time to 30% Reduction in eGFR | Placebo Oral Capsule | 39 | Participants | ||
| Part B: Time to Receiving Rescue Medication. | Nefecon | 15 | Participants | ||
| Part B: Time to Receiving Rescue Medication. | Placebo Oral Capsule | 20 | Participants | ||
| Part B: Ratio of UPCR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months | Nefecon | 0.60 | 95% Confidence Interval 0.54 to 0.66 | g/gram | |
| Part B: Ratio of UPCR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months | Placebo Oral Capsule | 1.01 | 95% Confidence Interval 0.91 to 1.12 | g/gram | |
| Part B: Ratio of UACR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months | Nefecon | 0.52 | 95% Confidence Interval 0.46 to 0.58 | g/gram | |
| Part B: Ratio of UACR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months | Placebo Oral Capsule | 0.96 | 95% Confidence Interval 0.86 to 1.08 | g/gram | |
| Part B: Ratio of eGFR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months | Nefecon | 0.93 | 95% Confidence Interval 0.90 to 0.96 | mL/min/1.73m2 | |
| Part B: Ratio of eGFR Compared to Baseline Averaged Over Time Points Between 12 and 24 Months | Placebo Oral Capsule | 0.84 | 95% Confidence Interval 0.81 to 0.86 | mL/min/1.73m2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03643965/results